ING Bank Slaski S.A. (ING)
Market Closed
12 Jun, 14:50
WSE 
zł
471. 00
+35
+8.0275%
zł
- Market Cap
- P/E Ratio
- Div Yield
77,417 Volume
- Eps
zł 436
Previous Close Want to track ING and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
ING closed today higher at zł471, an increase of 8.0275% from yesterday's close, completing a monthly increase of 8.776% or zł38. Over the past 12 months, ING stock gained 37.9209%.
ING pays dividends to its shareholders, with the most recent payment made on Apr 27, 2026. The next estimated payment will be in In 10 months on Apr 27, 2027 for a total of zł26.71.
The last earnings report, released on Apr 30, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 2.8468%, based on the last three reports.
ING Bank Slaski S.A. has completed 1 stock splits, with the recent split occurring on Nov 18, 2011.
The company's stock is traded on 5 different exchanges and in various currencies, with the primary listing on XFRA (EUR).
ING Chart
ING Bank Slaski S.A. (ING) FAQ
What is the stock price today?
The current price is zł471.00.
On which exchange is it traded?
ING Bank Slaski S.A. is listed on WSE.
What is its stock symbol?
The ticker symbol is ING.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, no market cap data is available.
Has ING Bank Slaski S.A. ever had a stock split?
ING Bank Slaski S.A. had 1 splits and the recent split was on Nov 18, 2011.
ING Bank Slaski S.A. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | - CEO | WSE Exchange | PLBSK0000017 ISIN |
| Germany Country | - Employees | 21 Apr 2026 Last Dividend | - Last Split | - IPO Date |
Overview
Cantourage Group SE is a notable presence in the European medical cannabis market, focusing on the provision of a range of cannabis-based medicinal products. With its inception in 2019, the company has quickly established itself in Kleinmachnow, Germany. Cantourage Group SE is dedicated to ensuring the availability of high-standard cannabis products to meet the growing demands in the pharmaceutical sector, emphasizing quality and therapeutic efficacy.
Products and Services
- Dried Flowers: These are carefully selected cannabis flowers offered for their medicinal properties. The drying process preserves the cannabinoids, terpenes, and other essential compounds, making them suitable for various medical applications, such as pain management, alleviating the symptoms of multiple sclerosis, and reducing nausea during chemotherapy.
- Extracts: Cantourage Group SE provides concentrated cannabis extracts. These extracts contain high levels of cannabinoids and are used in the formulation of medicinal products. They are designed for patients who require precise dosages of THC, CBD, or other cannabinoids, offering a more controlled intake than dried flowers.
- Dronabinol Products: Dronabinol, a synthetic form of THC, is available in several therapeutic formulations. These products aim at treating an assortment of conditions, including but not limited to, appetite loss in AIDS patients and nausea and vomiting caused by cancer chemotherapy. Dronabinol mimics the effects of natural cannabinoids, providing effective symptom relief.
- Pharma-grade Cannabidiol Products: These are pharmaceutical-grade CBD products, distinguished by their purity and quality. They cater to patients needing CBD for its therapeutic benefits without the psychoactive effects of THC. Common uses include treatment for epilepsy, anxiety disorders, and inflammatory diseases. Pharma-grade ensures the highest standard for safety and efficacy.
Contact Information
Address: Heinrich-Mann-Str. 12
Phone: 49 30 4701 350 50
Website: https://www.cantourage.com
